<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557531</url>
  </required_header>
  <id_info>
    <org_study_id>1040.01</org_study_id>
    <secondary_id>1040.01</secondary_id>
    <nct_id>NCT00557531</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility of the Injectable BL-1040 Implant</brief_title>
  <official_title>Safety and Feasibility of the Injectable BL-1040 Implant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLineRx, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BioLineRx, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, multi-center, open label study designed to assess the safety and&#xD;
      feasibility of the injectable BL-1040 implant to provide scaffolding to infarcted myocardial&#xD;
      tissue.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ENDPOINTS Preliminary safety endpoints Occurrence of all adverse events including but not&#xD;
      limited to All MIs Cardiovascular hospitalization&#xD;
&#xD;
      Serious ventricular arrhythmias sustained:&#xD;
&#xD;
      VT (symptomatic or sustained VT [duration longer than 30 seconds or 100 beats, or associated&#xD;
      with hemodynamic collapse]) VF symptomatic bradycardia, pauses of longer than 3.0 seconds,&#xD;
      complete atrioventricular block, Mobitz II atrioventricular block Symptomatic heart failure&#xD;
      (NYHA criteria + physical examination OR hospitalization due to heart failure) Renal failure&#xD;
      Stroke Death&#xD;
&#xD;
      Secondary safety endpoints Change from baseline in LV dimensions (end-systolic volume index,&#xD;
      end-diastolic volume index) Change from baseline in regional (infarct related) and global&#xD;
      wall motion score Change from baseline in ejection fraction Cardiac rupture NT-proBNP&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of all AEs including but not limited to All MIs CV hospitalization Serious ventricular arrhythmias sustained: Symptomatic heart failure Renal failure Stroke Death</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in LV dimensions (end-systolic volume index, end-diastolic volume index) Change from baseline in regional (infarct related) and global wall motion score Change from baseline in ejection fraction Cardiac rupture NT-proBNP</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>BL-1040</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BL-1040</intervention_name>
    <description>2 mL of BL-1040</description>
    <arm_group_label>BL-1040</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  18 to 75 years of age, inclusive&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Negative pregnancy test for women of child-bearing potential, or surgically sterile,&#xD;
             or post menopausal&#xD;
&#xD;
          -  Acute MI defined as:&#xD;
&#xD;
               -  Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of&#xD;
                  biochemical markers of myocardial necrosis with at least one of the following:&#xD;
&#xD;
                    -  Ischemic symptoms;&#xD;
&#xD;
                    -  Development of pathologic Qwaves on the ECG;&#xD;
&#xD;
                    -  ECG changes indicative of ischemia (ST segment elevation or depression)&#xD;
&#xD;
                    -  First anterior or inferolateral STEMI or Qwave MI (QMI Anterior: V1-V3 or&#xD;
                       V1-V4 or V1-V5 or V1-V6.QMI Inferior: L2, L3, AVF, or L2, L3, AVF+ V5, V6 or&#xD;
                       L2, L3, AVF+ V6-V9 [posterior leads])&#xD;
&#xD;
                    -  Regional wall motion score index (at least 4 out of 16 akinetic segments)&#xD;
&#xD;
          -  One or more of the following:&#xD;
&#xD;
               -  LVEF &gt;20% and &lt;45% measured and calculated by 2-dimensional measurement&#xD;
&#xD;
               -  Biomarkers: peak CK &gt; 2000 IU&#xD;
&#xD;
               -  Infarct size &gt; 25% as measured by MRI&#xD;
&#xD;
               -  Successful revascularization with PCI with 1 stent only, within 7 days of the&#xD;
                  index MI&#xD;
&#xD;
               -  At time of application of study device, patient must have patent infarct related&#xD;
                  artery (IRA) and TIMI flow grade = 3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of CHF, Class I to Class IV, as per NYHA criteria&#xD;
&#xD;
          -  History of prior LV dysfunction&#xD;
&#xD;
          -  At time of application of study device - Killip III-IV (pulmonary edema, cardiogenic&#xD;
             shock - hypotension systolic &lt; 90 mmHg and evidence of peripheral hypoperfusion&#xD;
             oliguria, cyanosis, sweating) or HR &gt; 100 bpm&#xD;
&#xD;
          -  Prior CABG&#xD;
&#xD;
          -  Prior MI&#xD;
&#xD;
          -  History of stroke&#xD;
&#xD;
          -  Significant valvular disease (moderate or severe)&#xD;
&#xD;
          -  Patient is a candidate for CABG or PCI on non-IRA&#xD;
&#xD;
          -  Patient is being considered for CRT within the next 30 days&#xD;
&#xD;
          -  Renal insufficiency (eGFR &lt; 60)&#xD;
&#xD;
          -  Chronic liver disease (&gt; 3 times upper limit of normal)&#xD;
&#xD;
          -  Life expectancy &lt; 12 months&#xD;
&#xD;
          -  Current participant in another clinical trial, or participation in another trial&#xD;
             within the last 6 months&#xD;
&#xD;
          -  Any contraindication to coronary angiography, MRI or PCI procedures&#xD;
&#xD;
          -  Patient taking anti-coagulation medication prior to MI&#xD;
&#xD;
          -  Pregnant or lactating women; pregnancy confirmed by urine pregnancy test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Vermeersch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antwerp MC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heidelberg University MC</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>November 12, 2007</study_first_submitted>
  <study_first_submitted_qc>November 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <last_update_submitted>February 2, 2012</last_update_submitted>
  <last_update_submitted_qc>February 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2012</last_update_posted>
  <responsible_party>
    <name_title>BioLineRx</name_title>
    <organization>Public Company</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>August 16, 2017</submitted>
    <returned>February 16, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

